Literature DB >> 33224742

Combination of serum TIMP-3, CA125, and NT-proBNP in predicting ventricular remodeling in patients with heart failure following acute myocardial infarction.

Yue-Tao Xie1, Yi Dang1, Fei-Fei Zhang1, Qian-Hui Zhang1, Hai-Bo Wu1, Guang Liu2.   

Abstract

BACKGROUND: Left ventricular remodeling is the basic pathological mechanism of heart failure following acute myocardial infarction (AMI). Determining sensitive indexes for the early prediction of ventricular remodeling is important for the prevention of heart failure. This study aims to investigate the value of serum TIMP-3, CA125, and NT-proBNP in predicting ventricular remodeling in patients with heart failure following AMI.
METHODS: From May 2017 to May 2018, 93 patients with heart failure following AMI were enrolled in the study. The participants were divided into two groups: the ventricular remodeling group (n=51) and the non-ventricular remodeling group (n=42). In addition, 47 healthy subjects who underwent physical examinations in the same period were enrolled as controls. Serum TIMP-3, CA125, and NT-proBNP were measured, in addition to the left ventricular wall thickness (LVWT) and left ventricular mass index (LVMI). The correlation of serum TIMP-3, CA125, and NT-proBNP with the LVWT and LVMI was analyzed, and its value in predicting ventricular remodeling was evaluated.
RESULTS: Serum TIMP-3 level was lower (P<0.05) and CA125 and NT-proBNP levels were higher (P<0.05) in both the ventricular remodeling and non-ventricular remodeling groups compared with the control group. Furthermore, the serum TIMP-3 level was lower in the ventricular remodeling group compared with the non-ventricular remodeling group (P<0.05), while the levels of CA125 and NT-proBNP were higher in the ventricular remodeling group compared with the non-ventricular remodeling group (P<0.05). The serum TIMP-3 level was negatively correlated with the LVWT and LVMI, while serum CA125 and NT-proBNP levels were positively correlated with the LVWT and LVMI, respectively. The area under the receiver operating characteristic curve of the combination of serum TIMP-3, CA125, and NT-proBNP levels in predicting ventricular remodeling was 0.850, and the prediction sensitivity and specificity were 74.51% and 87.71%, respectively.
CONCLUSIONS: The combination of serum TIMP-3, CA125, and NT-proBNP can improve the sensitivity and specificity of predicting ventricular remodeling and can aid in the early prevention and treatment of heart failure. 2020 Cardiovascular Diagnosis and Therapy. All rights reserved.

Entities:  

Keywords:  Acute myocardial infarction (AMI); N-terminal pro-brain natriuretic peptide (NT-proBNP); carbohydrate antigen CA125; heart failure; tissue inhibitor of matrix metalloproteinase 3

Year:  2020        PMID: 33224742      PMCID: PMC7666927          DOI: 10.21037/cdt-20-399

Source DB:  PubMed          Journal:  Cardiovasc Diagn Ther        ISSN: 2223-3652


  8 in total

1.  Amlodipine and Atorvastatin Improved Hypertensive Cardiac Remodeling through Regulation of MMPs/TIMPs in SHR Rats.

Authors:  Jingchao Lu; Jie Hao; Hong Du; Bing Xiao; Yue Li; Xiuchun Yang; Wei Cui
Journal:  Cell Physiol Biochem       Date:  2016-06-20

Review 2.  Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment.

Authors:  Marvin A Konstam; Daniel G Kramer; Ayan R Patel; Martin S Maron; James E Udelson
Journal:  JACC Cardiovasc Imaging       Date:  2011-01

3.  Carbohydrate antigen-125 and N-terminal pro-brain natriuretic peptide levels: compared in heart-failure prognostication.

Authors:  Serkan Ordu; Hakan Ozhan; Recai Alemdar; Mesut Aydin; Onur Caglar; Hatice Yuksel; Hayati Kandis
Journal:  Tex Heart Inst J       Date:  2012

Review 4.  Insights into the clinical implications of carbohydrate antigen 125 as a biomarker of heart failure: a meta-analysis and systematic review of published studies.

Authors:  Jianhui Zhuang; Pompilio Faggiano; Qi Li; Danitza Pradelli; Vet Med; Wenhui Peng; Mei Zuo; Yawei Xu
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2014-12       Impact factor: 2.160

5.  Local hydrogel release of recombinant TIMP-3 attenuates adverse left ventricular remodeling after experimental myocardial infarction.

Authors:  Shaina R Eckhouse; Brendan P Purcell; Jeremy R McGarvey; David Lobb; Christina B Logdon; Heather Doviak; Jason W O'Neill; James A Shuman; Craig P Novack; Kia N Zellars; Sara Pettaway; Roy A Black; Aarif Khakoo; Taeweon Lee; Rupak Mukherjee; Joseph H Gorman; Robert C Gorman; Jason A Burdick; Francis G Spinale
Journal:  Sci Transl Med       Date:  2014-02-12       Impact factor: 17.956

6.  Outcomes trends for acute myocardial infarction, congestive heart failure, and pneumonia, 2005-2009.

Authors:  Chapy Venkatesan; Alita Mishra; Amanda Morgan; Maria Stepanova; Linda Henry; Zobair M Younossi
Journal:  Am J Manag Care       Date:  2016-01-01       Impact factor: 2.229

7.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).

Authors:  Borja Ibanez; Stefan James; Stefan Agewall; Manuel J Antunes; Chiara Bucciarelli-Ducci; Héctor Bueno; Alida L P Caforio; Filippo Crea; John A Goudevenos; Sigrun Halvorsen; Gerhard Hindricks; Adnan Kastrati; Mattie J Lenzen; Eva Prescott; Marco Roffi; Marco Valgimigli; Christoph Varenhorst; Pascal Vranckx; Petr Widimský
Journal:  Eur Heart J       Date:  2018-01-07       Impact factor: 29.983

8.  Relation of Renal Function with Left Ventricular Systolic Function and NT-proBNP Level and Its Prognostic Implication in Heart Failure with Preserved versus Reduced Ejection Fraction: an analysis from the Korean Heart Failure (KorHF) Registry.

Authors:  Chan Soon Park; Jin Joo Park; Il-Young Oh; Chang-Hwan Yoon; Dong-Ju Choi; Hyun-Ah Park; Seok-Min Kang; Byung-Su Yoo; Eun-Seok Jeon; Jae-Joong Kim; Myeong-Chan Cho; Shung Chull Chae; Kyu-Hyung Ryu; Byung-Hee Oh
Journal:  Korean Circ J       Date:  2017-08-16       Impact factor: 3.243

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.